Enzalutamide 40mg
Product Overview
| Generic Name | Enzalutamide 40mg |
| Brand Name(s) | Xtandi®, Enzalu, Xylutide |
| Category | Antineoplastic / Cancer |
| Form | 112 Oral film-coated 40mg tablets |
| Strength | 40mg |
| Therapeutic Class | Androgen receptor inhibitor / androgen receptor signalling inhibitor |
| ATC Code | L02BB04 |
Manufacturing & Regulatory
| Manufacturer | Cipla, others |
| GMP Compliance | PIC/S, WHO |
| COFEPRIS | 010.000.6097.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 units |
| Shelf Life | 36 months |
| Storage | 20–25°C |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Yes, typically available as a lot/batch CoA |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | Full CTD dossier proprietary; available under commercial agreement/license |
Special Notes
Enzalutamide is an oral androgen receptor inhibitor used for prostate cancer, including castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence